Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (VIRAGE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05673811 |
Recruitment Status :
Recruiting
First Posted : January 6, 2023
Last Update Posted : April 19, 2024
|
Sponsor:
Theriva Biologics SL
Information provided by (Responsible Party):
Theriva Biologics SL
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | April 28, 2025 |
Estimated Study Completion Date : | April 28, 2025 |